Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
7567- HYP,    Hyperoside: A review on its sources, biological activities, and molecular mechanisms
- Review, Var, NA
*AntiCan↑, *Bacteria↓, *AntiViral↑, *antiD↓, *RenoP↑, *hepatoP↑, *eff↑, *Sepsis↓, *AntiArt↑, *Stroke↓, TumCMig↓, TumCI↓, MTA1↓, TIMP2↓, MMP2↓, MMP↓, Cyt‑c↑, Akt↓, mTOR↓, P70S6K↓, TumAuto↑, PD-L1↓, TNF-α↓, IL1β↓, IL6↓, IL8↓, Bcl-2↓, Bcl-xL↓, BAX↑, BAD↑, Bak↑, VEGF↓, Casp3↑, Casp8↑, P53↑, GSH↓, SOD↓, Catalase↓, TAC↓, XIAP↓, ROS↓, NF-kB↓, TLR4↓, P-gp/ABCB1↓, LRP1↓, Fas↑, p27/CDKN1B↑, *cardioP↑, *AntiThr↑, *PAI-1/SERPINE1↓, *BUN↓, *ALAT↓, *AST↓, *neuroP?,
7566- HYP,    Hyperoside improves learning and memory deficits by amyloid β1-42 in mice through regulating synaptic calcium-permeable AMPA receptors
- in-vivo, AD, NA
*Learn↑, *memory↑, *Aβ↓,
7565- HYP,    Potential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review
- Review, AD, NA
*Inflam↓, *antiOx↑, *neuroP↑, *lipid-P↓, *ROS↓, *IL1β↓, *IL6↓, *IL8↓, *TNF-α↓, *MDA↓, *BAX↓, *Casp3↓, *Catalase↑, *SOD↑, *GSH↑, *BDNF↑, *TrkB↑, *NGF↑, *BDNF↑, *NF-kB↓, *AChE↓, *H2S↑, Casp3↑, Apoptosis↑, NF-kB↓, AMPK↑, HO-1↑, MAPK↑, cl‑Casp3↑, cl‑Casp9↑, BAX↑, SOD?, Catalase↓, NRF2↓, NQO1↓, HO-1↓, Bcl-2↓, TumCCA↑, FOXO1↑, TumAuto↑, Akt↓, mTOR↓, P70S6K↓, BMP7/OP1↓, *cardioP↑, *hepatoP↑, *antiCG↑, *AntiThr↑, *Diar↓, *AntiFungal↑, *CYP2D6↓, *PDGFR-BB↓, *PDGFRB↓, *toxicity↓, *Half-Life↑,
7564- HYP,    Pharmacological activities and therapeutic potential of Hyperoside in the treatment of Alzheimer's and Parkinson's diseases: A systemic review
- Review, AD, NA - Review, Park, NA
*antiOx↑, *Inflam↓, *Apoptosis↓, *Aβ↓, *AChE↓,
7562- HYP,  doxoR,    Hyperoside Inhibits Doxorubicin-Induced Ferroptosis in Cardiomyocytes via the Nrf2/GPX4 Pathway
- in-vivo, Nor, NA
*ROS↓, *Ferroptosis↓, *Apoptosis↓, *cardioP↑, *MDA↓, *SOD↑, *GPx↑, *i-Iron↓, *4-HNE↓, *GSH↑, *Ferritin↑, *ACSL4↓, *NRF2↑, *GPx4↑,
7563- HYP,    Hyperoside alleviates macrophages and microglia-mediated neuroinflammation and oxidative stress through activating PI3K/AKT and Nrf2/HO-1 signaling pathway post spinal cord injury
- vitro+vivo, Nor, NA
*Inflam↓, *antiOx↑, *Dose↝, *IL1β↓, *IL6↓, *TNF-α↓, *iNOS↓, *COX2/PTGS2↓, *NOX4↓, *NOX2↓, *NOX1↓, *PI3K↑, *Akt↑, *NRF2↑, *HO-1↑, *neuroP↑,
7548- HYP,    Mechanistic evaluation of hyperoside against non-small cell lung cancer: a combined approach of network pharmacology and in vitro experimental validation
- in-vitro, NSCLC, A549
MMP9↓, cl‑Casp3↑, MAPK↑, EGFR↓, TumCP↓, p38↑, Apoptosis↑, BAX↑, ERK↓, FOXO1↓,
7547- HYP,    Hyperoside suppresses NSCLC progression by inducing ATG13-mediated autophagy and apoptosis
- vitro+vivo, NSCLC, NA
TumCMig↓, TumCP↓, TumCG↓, Apoptosis↑, TumCCA↑, TumAuto↑, ATG13↑,
7546- HYP,    Hyperoside attenuates hydrogen peroxide-induced L02 cell damage via MAPK-dependent Keap₁-Nrf₂-ARE signaling pathway
- in-vitro, Nor, L02
*TAC↑, *GPx↑, *Catalase↑, *ROS↓, *MMP↓, *LDH↑, *HO-1↑, *NRF2↑,
7549- HYP,  Rad,    Study on the mechanism of hyperoside in affecting the biological progression and radiosensitivity of esophageal carcinoma by modulating the STAT3/AKT/ERK pathway
- vitro+vivo, ESCC, TE1 - vitro+vivo, ESCC, KYSE150
TumCP↓, TumCI↓, TumCMig↓, EMT↓, Apoptosis↑, RadioS↑, p‑STAT3↓, p‑Akt↓, p‑ERK↓,
7545- HYP,    Hyperoside induces ferroptosis in chronic myeloid leukemia cells by targeting NRF2
- in-vitro, CML, K562
xCT/SLC7A11↓, GPx4↓, Ferroptosis↑, ROS↑, lipid-P↑, mtDam↑, NRF2↓,
7550- HYP,    Hyperoside Induces Breast Cancer Cells Apoptosis via ROS-Mediated NF-κB Signaling Pathway
- in-vitro, BC, MCF7 - in-vitro, BC, 4T1
*Inflam↓, AntiCan↑, tumCV↓, TumCMig↓, Apoptosis↑, Bcl-2↓, XIAP↓, BAX↑, cl‑Casp3↑, ROS↓, NF-kB↓, TumVol↓,
7551- HYP,    Hyperoside exhibits anticancer activity in non‑small cell lung cancer cells with T790M mutations by upregulating FoxO1 via CCAT1
- vitro+vivo, NSCLC, NA
TumCP↓, Apoptosis↑, FOXO1↑, CCAT1↓, TumCG↓,
7552- HYP,    Hyperoside exerts potent anticancer activity in skin cancer
- vitro+vivo, Melanoma, NA
AntiCan↑, *Inflam↓, *antiOx↑, PI3K↓, Akt↓, mTOR↓, TumCP↓, Apoptosis↑, TumAuto↑, chemoPv↑,
7554- HYP,    Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism
- in-vitro, NSCLC, A549
tumCV↓, Apoptosis↑, p‑MAPK↑, JNK↑, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, AIF↑,
7555- HYP,  RT,    Hyperoside and rutin of Nelumbo nucifera induce mitochondrial apoptosis through a caspase-dependent mechanism in HT-29 human colon cancer cells
- in-vitro, Colon, HT29
tumCV↓, Apoptosis↑, BAX↑, Bcl-2↓, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑,
7556- HYP,    Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway both in vitro and in vivo
- vitro+vivo, PC, NA
TumCP↓, Apoptosis↑, Bax:Bcl2↑, NF-kB↓, TumCG↓,
7558- HYP,    The Cytoprotective Effect of Hyperoside against Oxidative Stress Is Mediated by the Nrf2-ARE Signaling Pathway through GSK-3β Inactivation
- in-vivo, AD, NA
*ROS↓, *NRF2↑, *ARE↑, *HO-1↑, *GSK‐3β↑, *Keap1↓, *eff↑,
7553- HYP,    Hyperoside induces both autophagy and apoptosis in non-small cell lung cancer cells in vitro
- in-vitro, NSCLC, A549 - in-vitro, Nor, BEAS-2B
LC3II↑, selectivity↑, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, p‑4E-BP1↓, p‑ERK↑, tumCV↓, Apoptosis↑,
7561- HYP,    Hyperoside Exerts Therapeutic Effects on Parkinson's Disease by Mitigating Oxidative Stress through Activation of Nrf2/HO-1 Pathway
- in-vivo, Park, NA
*motorD↑, *NRF2↑, *HO-1↑, *Bcl-2↑, *BAX↓, *GSH↑, *GPx↑, *SOD↑, *Catalase↑, *MDA↓, *Apoptosis↓,
7560- HYP,    Hyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity
- Review, Nor, NA - Review, AD, NA
*RenoP↓, Casp3↑, Casp8↑, MDA↑, GSH↓, SOD↓, Catalase↓, VEGF↓, Bcl-2↓, TumCG↓, p‑Akt↓, PI3K↓, TumCCA↑, TumCP↓, BMP7/OP1↓, *ZO-1↑, *BBB↝, *p‑Akt↑, *GSK‐3β↑, *SOD↑, *Catalase↑, *GSH↑, *SIRT1↑, *NF-kB↓, *IL1β↓, *IL6↓, *IL8↓, *TNF-α↓, *ROS↓, *MDA↓, *BAX↓, *Casp3↓, *Bcl-2↑, *BDNF↑, *TrkB↑, *NGF↑, *Apoptosis↓, *cardioP↑, *AST↓, *hepatoP↑, *AST↓, *ALAT↓, *MDA↓, *BACH1↓, *neuroP↑, *Stroke↓, *ICAM-1↓, *VCAM-1↓, *TLR4↓, *COX2/PTGS2↓, *RenoP↑, *NLRP3↓, *Casp1↓, *ASC↓, *BioAv↓, *BioAv↑, *toxicity↓,
7544- HYP,    Long-term oral administration of hyperoside ameliorates AD-related neuropathology and improves cognitive impairment in APP/PS1 transgenic mice
- in-vivo, AD, NA
*Learn↑, *memory↑, *Aβ↓, *p‑tau↓, *Inflam↓, *ROS↓, *BACE/β-secretase↓, *GSK‐3β↓,
7596- I3C,    Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent
- in-vitro, BC, NA
TumCG↓, selectivity↑, P450↑,
7600- I3C,    Indole-3-Carbinol (I3C) and its Major Derivatives: Their Pharmacokinetics and Important Roles in Hepatic Protection
- Review, Nor, NA
*ROS↓, *hepatoP↑, *AntiTum↑, *Imm↑, *Inflam↓,
7601- I3C,    Prevention and treatment of cancer with indole-3-carbinol
- Review, BC, NA
Estro↝, 2/16-OHE1↑, chemoPv↑,
7602- I3C,    Dose-ranging study of indole-3-carbinol for breast cancer prevention
- Trial, BC, NA
toxicity↓, Dose↝, 2/16-OHE1↑, chemoPv↑,
7603- I3C,    Modulation of CYP19 expression by cabbage juices and their active components: indole-3-carbinol and 3,3′-diindolylmethene in human breast epithelial cell lines
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF-10AT
CYP19↓, Apoptosis↑,
7604- I3C,    Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent
2/16-OHE1↑, CYP1B1↓, 4-OHE1↓, Apoptosis↑, cycD1/CCND1↓, TumCCA↑, AntiTum↑,
7605- I3C,    Indole-3-carbinol and prostate cancer
- Review, Pca, NA
Risk↓, TumCCA↑, Apoptosis↑, Akt↓, NF-kB↓, ChemoSen↑,
7606- I3C,    Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol
- Human, Nor, NA
P450↝, 2/16-OHE1↑,
7607- I3C,    Indole-3-carbinol induces G1 cell cycle arrest and apoptosis through aryl hydrocarbon receptor in THP-1 monocytic cell line
- in-vitro, AML, THP1
AhR↑, TumCP↓, selectivity↑, Bcl-2↓, Fas↑, P21↑, p27/CDKN1B↑, P53↓, CDK2↓,
7608- I3C,    Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells
- in-vitro, Pca, PC3
AntiTum↑, TumCG↓, TumCCA↑, Apoptosis↑, Akt↓, EGF↓, PI3K↓, Bcl-xL↓, BAD↓,
7609- I3C,    Molecular Targets, Anti-cancer Properties and Potency of Synthetic Indole-3-carbinol Derivatives
- Review, Var, NA
AntiCan↑, tumCV↓, HIF-1↓, NF-kB↓, IGF-1↓, PI3K↓, Akt↓, Wnt↓, EstroRS/ERS↓,
7610- I3C,    Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line
- in-vitro, BC, MDA-MB-468 - in-vitro, Nor, HBL-100 - in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
Akt↓, selectivity↑, Apoptosis↑,
7611- I3C,    Long-term responses of women to indole-3-carbinol or a high fiber diet
- Trial, Nor, NA
*Dose↝, *2/16-OHE1↑,
7612- I3C,    Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells
- in-vitro, Nor, MCF10
selectivity↑, Bax:Bcl2↓, Bcl-xL↓, BAX↑, MMP↓, Cyt‑c↑, TumCD↑,
7587- I3C,    Indole-3-Carbinol, a Phytochemical Aryl Hydrocarbon Receptor-Ligand, Induces the mRNA Overexpression of UBE2L3 and Cell Proliferation Arrest
- in-vitro, Cerv, HeLa
AhR↑, UBE2L3/UBCH7↑, Dose↝,
7595- I3C,    Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans
- Human, Nor, NA
*Dose↝, *other↓, *chemoPv↑,
7580- I3C,    Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane
- Trial, NA, NA
Dose↝, BioAv↝, Dose↝,
7581- I3C,    A phase I study of indole-3-carbinol in women: tolerability and effects
- Trial, Nor, NA
CYP1A2↑, Dose↝,
7582- I3C,    Indole-3-Carbinol Promotes Apoptosis and Inhibits the Metastasis of Esophageal Squamous Cell Carcinoma by Downregulating the Wnt/β-Catenin Signaling Pathway
- vitro+vivo, ESCC, NA
Apoptosis↑, TumCMig↓, TumCI↓, β-catenin/ZEB1↓, cMyc↓, cycD1/CCND1↓,
7583- I3C,    Indole-3-carbinol prevented tumor progression and potentiated PD1ab therapy by upregulating PTEN in colorectal cancer
- vitro+vivo, CRC, NA
TumCP↓, TumCMig↓, toxicity↓, PTEN↑, CD8+↑,
7584- I3C,    Functional effect of indole-3 carbinol in the viability and invasive properties of cultured cancer cells
- in-vitro, Cerv, HeLa - in-vitro, CRC, HCT8 - in-vitro, Liver, HepG2
TumCP↓, Apoptosis↑, TumCI↓, *antiOx↑, AhR↑, MMP↓, Casp3↑, Casp8↑,
7585- I3C,    Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells
- in-vitro, BC, NA
Apoptosis↑, selectivity↑, Akt↓, NF-kB↓,
7586- I3C,    Bax translocation to mitochondria is an important event in inducing apoptotic cell death by indole-3-carbinol (I3C) treatment of breast cancer cells
- in-vitro, BC, NA
TumCG↓, Apoptosis↑, BAX↑, Bcl-2↓, MMP↓, Cyt‑c↑, TumCCA↑,
7588- I3C,    Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells
- in-vitro, AML, NA
TumCG↓, TumCCA↑, Apoptosis↑, P53↑, P21↑, BAX↑, PUMA↑, NOXA↑, APAF1↑, NF-kB↓, IAP1↓, Bcl-xL↓, Bcl-2↓, XIAP↓, Myc↓, ChemoSen↑, Casp9↑, cl‑PARP↑, eff↑,
7589- I3C,    Indole-3-carbinol inhibits cell proliferation and induces apoptosis in Hep-2 laryngeal cancer cells
- vitro+vivo, Laryn, HEp2
TumCP↓, Apoptosis↑, PI3K↓, Akt↓, GSK‐3β↓, TumVol↓, *toxicity↓,
7590- I3C,    Indole-3-carbinol synergistically sensitises ovarian cancer Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatmentcells to bortezomib treatment
- in-vivo, Ovarian, NA
ChemoSen↑, TumCG↓, TumW↓,
7591- I3C,    Indole-3-carbinol (I3C)-induced apoptosis in nasopharyngeal cancer cells through Fas/FasL and MAPK pathway
- in-vitro, NPC, CNE2
Apoptosis↑, MMP↓, XIAP↓, IAP1↓, survivin↓, Diablo↑, Cyt‑c↑, HTRA2/Omi/PARK13↑, mtDam↑, Fas↑, FasL↑,
7592- I3C,    Indole-3-carbinol as a chemopreventive and anti-cancer agent
- Review, Var, NA
JNK↑, STAT3↓, TumCCA↑, P21↑, p27/CDKN1B↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, AhR↑, ER-α36↓, ChemoSen↑, ER Stress↑, UPR↑, BRCA1↑, BRCA2↑, TumCMig↓, TumCI↓, VEGF↓, IL8↓, MMP2↓, MMP9↓, RadioS↑, Akt↓, NF-kB↓, DR4↑, DR5↑,

Showing Research Papers: 4801 to 4850 of 8269
Prev Page 97 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

2/16-OHE1↑, 4,   4-OHE1↓, 1,   ATG13↑, 1,   BMP7/OP1↓, 2,   HTRA2/Omi/PARK13↑, 1,   MTA1↓, 1,   UBE2L3/UBCH7↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 3,   Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 2,   HO-1↓, 1,   HO-1↑, 1,   lipid-P↑, 1,   MDA↑, 1,   NQO1↓, 1,   NRF2↓, 2,   ROS↓, 2,   ROS↑, 1,   SOD?, 1,   SOD↓, 2,   TAC↓, 1,   xCT/SLC7A11↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   EGF↓, 1,   MMP↓, 6,   mtDam↑, 2,   XIAP↓, 4,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   cMyc↓, 1,  

Cell Death(tgid=5) ⓘ

AhR↑, 4,   Akt↓, 10,   p‑Akt↓, 3,   APAF1↑, 1,   Apoptosis↑, 23,   BAD↓, 1,   BAD↑, 1,   Bak↑, 1,   BAX↑, 8,   Bax:Bcl2↓, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 8,   Bcl-xL↓, 4,   Casp3↑, 5,   cl‑Casp3↑, 4,   Casp8↑, 3,   cl‑Casp8↑, 1,   Casp9↑, 2,   cl‑Casp9↑, 2,   Cyt‑c↑, 5,   Diablo↑, 1,   DR4↑, 1,   DR5↑, 1,   Fas↑, 3,   FasL↑, 1,   Ferroptosis↑, 1,   IAP1↓, 2,   JNK↑, 2,   MAPK↑, 2,   p‑MAPK↑, 1,   Myc↓, 1,   NOXA↑, 1,   p27/CDKN1B↑, 3,   p38↑, 1,   PUMA↑, 1,   survivin↓, 1,   TumCD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 5,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3II↑, 1,   TumAuto↑, 4,  

DNA Damage & Repair(tgid=10) ⓘ

BRCA1↑, 1,   BRCA2↑, 1,   CYP1B1↓, 1,   P53↓, 1,   P53↑, 2,   cl‑PARP↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 2,   CDK4↓, 1,   cycD1/CCND1↓, 3,   cycE/CCNE↓, 1,   P21↑, 3,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑4E-BP1↓, 1,   EMT↓, 1,   ERK↓, 1,   p‑ERK↓, 1,   p‑ERK↑, 1,   FOXO1↓, 1,   FOXO1↑, 2,   GSK‐3β↓, 1,   IGF-1↓, 1,   mTOR↓, 3,   p‑mTOR↓, 1,   P70S6K↓, 2,   p‑P70S6K↓, 1,   PI3K↓, 5,   PTEN↑, 1,   STAT3↓, 1,   p‑STAT3↓, 1,   TumCG↓, 9,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

CCAT1↓, 1,   ER-α36↓, 1,   LRP1↓, 1,   MMP2↓, 2,   MMP9↓, 2,   TIMP2↓, 1,   TumCI↓, 5,   TumCMig↓, 7,   TumCP↓, 11,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,   HIF-1↓, 1,   VEGF↓, 3,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   IL6↓, 1,   IL8↓, 2,   NF-kB↓, 9,   PD-L1↓, 1,   TLR4↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 1,   CYP19↓, 1,   Estro↝, 1,   EstroRS/ERS↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   ChemoSen↑, 4,   CYP1A2↑, 1,   Dose↝, 5,   eff↑, 1,   P450↑, 1,   P450↝, 1,   RadioS↑, 2,   selectivity↑, 6,  

Clinical Biomarkers(tgid=22) ⓘ

BRCA1↑, 1,   EGFR↓, 1,   EstroRS/ERS↓, 1,   IL6↓, 1,   Myc↓, 1,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   AntiTum↑, 2,   chemoPv↑, 3,   Risk↓, 1,   toxicity↓, 2,   TumVol↓, 2,   TumW↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 1,  
Total Targets: 151

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

2/16-OHE1↑, 1,   AntiArt↑, 1,   antiCG↑, 1,   antiD↓, 1,   CYP2D6↓, 1,   Learn↑, 2,   NOX1↓, 1,   NOX2↓, 1,   Stroke↓, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

4-HNE↓, 1,   antiOx↑, 5,   ARE↑, 1,   Catalase↑, 4,   Ferroptosis↓, 1,   GPx↑, 3,   GPx4↑, 1,   GSH↑, 4,   HO-1↑, 4,   i-Iron↓, 1,   Keap1↓, 1,   lipid-P↓, 1,   MDA↓, 5,   NOX4↓, 1,   NRF2↑, 5,   ROS↓, 7,   SOD↑, 4,   TAC↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↓, 1,   ALAT↓, 2,   BUN↓, 1,   H2S↑, 1,   LDH↑, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 1,   p‑Akt↑, 1,   Apoptosis↓, 4,   BAX↓, 3,   Bcl-2↑, 2,   Casp1↓, 1,   Casp3↓, 2,   Ferroptosis↓, 1,   iNOS↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 2,   other↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

GSK‐3β↓, 1,   GSK‐3β↑, 2,   PDGFRB↓, 1,   PI3K↑, 1,  

Migration(tgid=13) ⓘ

BACH1↓, 1,   PAI-1/SERPINE1↓, 1,   VCAM-1↓, 1,   ZO-1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

PDGFR-BB↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↝, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↓, 1,   COX2/PTGS2↓, 2,   ICAM-1↓, 1,   IL1β↓, 3,   IL6↓, 3,   IL8↓, 2,   Imm↑, 1,   Inflam↓, 7,   NF-kB↓, 2,   TLR4↓, 1,   TNF-α↓, 3,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 2,   BDNF↑, 3,   NGF↑, 2,   p‑tau↓, 1,   TrkB↑, 2,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 3,   BACE/β-secretase↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   Dose↝, 3,   eff↑, 2,   Half-Life↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 3,   Ferritin↑, 1,   IL6↓, 3,   LDH↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   cardioP↑, 4,   chemoPv↑, 1,   hepatoP↑, 4,   memory↑, 2,   motorD↑, 1,   neuroP?, 1,   neuroP↑, 3,   RenoP↓, 1,   RenoP↑, 2,   toxicity↓, 3,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   AntiViral↑, 1,   Bacteria↓, 1,   Diar↓, 1,   Sepsis↓, 1,  
Total Targets: 102

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page